CEO Pavan Cheruvu (Sio Gene Therapies)
November 10, 2020 07:00 AM ESTUpdated 07:16 AM
People
Cell/Gene Tx

'We're not a van­t': Ax­o­vant seeks to for­get the past as the com­pa­ny re­brands to Sio Gene Ther­a­pies

Max Gelman

Senior Editor

Aim­ing to shed the lega­cy of an epic Alzheimer’s fail a few years ago, Ax­o­vant $AXGT is chang­ing its name in a full cor­po­rate …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Halozyme with­draws Evotec ac­qui­si­tion pro­pos­al af­ter biotech is 'un­will­ing to en­gage'

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times